IMA, US45175G2075

IMA stock gains after ImageneBio grants employee awards

Published on 10/07/2026 at 05:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

IMA stock gained 1.28 percent to USD 4.760 on October 6, 2026, after 90,775 restricted stock units were granted. Q2 GAAP loss reached USD 10.18 million.

IMA, US45175G2075, Illustration mit AI erstellt.

IMA stock (ISIN US45175G2075) gained 1.28 percent to USD 4.760 on NASDAQ at 10:47 a.m. ET on October 6, 2026. The move followed ImageneBio's announcement of equity awards for three newly hired employees, putting compensation and potential dilution alongside the company's clinical development story.

Employee awards set the latest catalyst

According to StockTitan on October 2, 2026, ImageneBio granted 90,775 restricted stock units and 32,725 non-qualified stock options under Nasdaq Listing Rule 5635(c)(4). The options carry an exercise price of USD 4.58 per share, matching the September 30, 2026 closing price.

The awards vest over four years. For investors, the key trade-off is clear: the grants support recruitment in a clinical-stage biotech, while the eventual share delivery can increase dilution.

Quarterly loss widened sharply

Markets Insider reported on October 1, 2026, that ImageneBio posted a quarterly GAAP net loss of USD 10.18 million for the quarter ended June 30, 2026, versus USD 2.77 million a year earlier. The same report cited Q2 adjusted? No, it identified the result as GAAP and also noted earnings per share of USD 0.63 below consensus of USD 0.98.

ImageneBio is developing immunology treatments, including the non-depleting anti-OX40 antibody olevaprubart. Its current Phase 2b study in moderate-to-severe atopic dermatitis makes clinical progress a more material valuation driver than near-term revenue.

Analysts split on the valuation

MarketBeat lists a Hold consensus based on four analyst ratings as of October 6, 2026. The average 12-month price target is USD 29.00, with a high of USD 30.00 and a low of USD 28.00; the average target lies 509.2 percent above the October 6 price of USD 4.760.

IMA stock stays below its yearly high

IMA stock had a market capitalization of USD 51.9 million and a volume of 13,568 shares on October 6, 2026. Its 52-week range was USD 3.94 to USD 9.10 as of October 2, 2026, leaving the latest price 47.7 percent below the yearly high.